Iron availability and complex stability of iron hydroxyethyl starch and iron dextran—a comparative in vitro study with liver cells and macrophages

Background. Intravenous iron (IVI) therapy is required in patients with end-stage renal disease (ESRD) under chronic haemodialysis (HD). In this in vitro study we investigated the availability and stability of iron hydroxyethyl starch (iron-Hes) compounds in THP-1 cells (macrophage phenotype) and li...

Full description

Saved in:
Bibliographic Details
Published in:Nephrology, dialysis, transplantation dialysis, transplantation, 2007-10, Vol.22 (10), p.2824-2830
Main Authors: Ternes, Nina, Scheiber-Mojdehkar, Barbara, Landgraf, Grit, Goldenberg, Hans, Sturm, Brigitte
Format: Article
Language:English
Subjects:
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Biological and medical sciences
Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis
Blood. Blood coagulation. Reticuloendothelial system
Cell Line
Chelating Agents - pharmacology
Dextrans - metabolism
Dose-Response Relationship, Drug
Emergency and intensive care: renal failure. Dialysis management
Enzyme-Linked Immunosorbent Assay
Ferritins - chemistry
Ferritins - metabolism
HepG2
Humans
Hydroxyethyl Starch Derivatives - pharmacology
in vitro
In Vitro Techniques
Intensive care medicine
intravenous iron therapy
Iron - blood
Iron - chemistry
Iron - pharmacology
iron dextran
iron hydroxyethyl starch
Liver - cytology
Liver - metabolism
Macrophages - cytology
Macrophages - metabolism
Medical sciences
Oxidation-Reduction
Pharmacology. Drug treatments
THP-1
Time Factors
Transfusions. Complications. Transfusion reactions. Cell and gene therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. Intravenous iron (IVI) therapy is required in patients with end-stage renal disease (ESRD) under chronic haemodialysis (HD). In this in vitro study we investigated the availability and stability of iron hydroxyethyl starch (iron-Hes) compounds in THP-1 cells (macrophage phenotype) and liver cells (HepG2 cells) and compared it with the well-known iron dextran. Methods. The uptake and release of these iron formulations by THP-1 cells (macrophage phenotype) and HepG2 cells were investigated with atomic absorption spectrometry (AAS). Ferritin was measured by ELISA. HepG2 cells were used to investigate effects of IVI on the intracellular labile iron pool (LIP), which was measured by using the fluorescent calcein assay. The amount of redox-active iron within the iron formulations was assayed using dichlorofluorescein as fluorescent probe. Results. All iron preparations were taken up, stored in ferritin and released again by macrophages and HepG2-cells. This study shows that the availability and stability of iron-HES formulations in vitro are comparable with the well-known iron dextran compounds. Conclusions. Our results indicate that these new iron formulations have a good stability and availability in vitro and are comparable with the well-known iron dextran complexes.
ISSN:0931-0509
1460-2385
DOI:10.1093/ndt/gfm315